Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I.
Rocket could file for approval in both programs as early as next year, with potential pre-BLA meetings in 2022.
Despite the known risks, Raymond James thinks experts favor LVV-based gene therapies in rare pediatric diseases.
Related: Rocket Pharma's ... Full story available on Benzinga.com